Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant Gemcitabine and Radiotherapy in Rectal Adenocarcinoma
NCT02919878Phase 2Unknown
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- Dec 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in rectal adenocarcinoma, sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoint: Pathological Complete Response Rate at 3 years. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT02919878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919878.